UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

Cancer chemotherapy and pharmacology, 2008-12, Vol.63 (1), p.157-166

2008

Volltextzugriff (PDF)

Metabolism and disposition of dasatinib after oral administration to humans

Drug metabolism and disposition, 2008-07, Vol.36 (7), p.1357-1364

2008

Volltextzugriff (PDF)

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

Cancer chemotherapy and pharmacology, 2009, Vol.63 (2), p.201-212

2009

Volltextzugriff (PDF)

The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

Cancer research (Chicago, Ill.), 2006-06, Vol.66 (11), p.5790-5797

2006

Volltextzugriff (PDF)

Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid

Bioorganic & medicinal chemistry letters, 2010-08, Vol.20 (15), p.4578-4581

2010

Volltextzugriff (PDF)

Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy

Science advances, 2019-02, Vol.5 (2), p.eaav2437-eaav2437

2019

Volltextzugriff (PDF)

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models

Cancer immunology research, 2017-02, Vol.5 (2), p.157-169

2017

Volltextzugriff (PDF)

SAR and pH Stability of Cyano-Substituted Epothilones

Organic letters, 2002-10, Vol.4 (22), p.3815-3818

2002

Volltextzugriff (PDF)

Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models

Clinical cancer research, 2008-12, Vol.14 (24), p.8123-8131

2008

Volltextzugriff (PDF)

Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models

Cancer research (Chicago, Ill.), 2004-06, Vol.64 (11), p.3974-3980

2004

Volltextzugriff (PDF)

In vivo Evaluation of Ixabepilone (BMS247550), A Novel Epothilone B Derivative, against Pediatric Cancer Models

Clinical cancer research, 2005-10, Vol.11 (19), p.6950-6958

2005

Volltextzugriff (PDF)

Discovery of (R)-7-Cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a Farnesyltransferase Inhibitor with Potent Preclinical Antitumor Activity

Journal of medicinal chemistry, 2000-10, Vol.43 (20), p.3587-3595

2000

Volltextzugriff (PDF)

A Novel Application of a Pd(0)-Catalyzed Nucleophilic Substitution Reaction to the Regio- and Stereoselective Synthesis of Lactam Analogues of the Epothilone Natural Products

Journal of the American Chemical Society, 2000-09, Vol.122 (37), p.8890-8897

2000

Volltextzugriff (PDF)

Abstract 1145: AGX323 - A SAM-competitive, orally available inhibitor of protein arginine methyltransferase 5 (PRMT5) with potent cellular antiproliferative and in vivo antitumor activity against selected solid cancer types

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1145-1145

2021

Volltextzugriff (PDF)

Synthesis and Biological Activity of Novel Epothilone Aziridines

Organic letters, 2001-08, Vol.3 (17), p.2693-2696

2001

Volltextzugriff (PDF)

Preclinical Pharmacology of BMS-275183, an Orally Active Taxane

Clinical cancer research, 2001-07, Vol.7 (7), p.2016-2021

2001

Volltextzugriff (PDF)

Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies

Molecular cancer therapeutics, 2009-01, Vol.8 (1), p.17-25

2009

Volltextzugriff (PDF)

Abstract IA10: Developing rational combination therapy with checkpoint inhibitors

Clinical cancer research, 2020-08, Vol.26 (15_Supplement), p.IA10-IA10

2020

Volltextzugriff (PDF)

BMS-247550 : A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy

Clinical cancer research, 2001-05, Vol.7 (5), p.1429-1437

2001

Volltextzugriff (PDF)

Development of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular and in Vivo Activity

Journal of medicinal chemistry, 1996-01, Vol.39 (1), p.224-236

1996

Volltextzugriff (PDF)

Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor

Cancer research (Chicago, Ill.), 2001-10, Vol.61 (20), p.7507-7517

2001

Volltextzugriff (PDF)

Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies

Molecular cancer therapeutics, 2009-01, Vol.8 (1), p.17-25

2009

Volltextzugriff (PDF)

1 – 25 von 453

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(412)
Mit Volltextzugriff
(390)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

Metabolism and disposition of dasatinib after oral administration to humans

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent

The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid

Correction to N‑(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N‑[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent

Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models

SAR and pH Stability of Cyano-Substituted Epothilones

Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models

Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models

In vivo Evaluation of Ixabepilone (BMS247550), A Novel Epothilone B Derivative, against Pediatric Cancer Models

Discovery of (R)-7-Cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a Farnesyltransferase Inhibitor with Potent Preclinical Antitumor Activity

A Novel Application of a Pd(0)-Catalyzed Nucleophilic Substitution Reaction to the Regio- and Stereoselective Synthesis of Lactam Analogues of the Epothilone Natural Products

Abstract 1145: AGX323 - A SAM-competitive, orally available inhibitor of protein arginine methyltransferase 5 (PRMT5) with potent cellular antiproliferative and in vivo antitumor activity against selected solid cancer types

Synthesis and Biological Activity of Novel Epothilone Aziridines

Preclinical Pharmacology of BMS-275183, an Orally Active Taxane

Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies

Abstract IA10: Developing rational combination therapy with checkpoint inhibitors

BMS-247550 : A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy

Development of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular and in Vivo Activity

Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor

Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies

Suchergebnisse filtern